[HIRING] SAMSUNG Bioepis Foreign Experienced Research & Development (R&D) Recruitment Announcement
- Writer
- 이남용
- Views
- 820
- 작성일
- 2025.02.27
Samsung Bioepis is committed to providing high-quality medicines to patients more efficiently and quickly, based on youthful and innovative thinking. Since its establishment in 2012, the company has launched products in immunology and oncology, and it became the first company to receive approval for three biosimilar products for autoimmune diseases in Europe, growing into a global leader in the biosimilar field.
Samsung Bioepis is currently recruiting experienced foreign nationals in the R&D field, and we welcome your interest.
★ Job Posting Link: https://www.samsungcareers.com/hr/?no=19471
★ Job Title: Foreign National Experienced Research & Development (R&D) Recruitment
★ Online Job Information Session Date & Time: Wednesday, February 28, 2025, 5:00 PM - 6:00 PM
★ Online Job Information Session Registration Link: https://forms.gle/3TAny1NZ7TyN7dkd6
If you wish to participate in the job information session, please complete the survey form by 10:00 AM on February 27, 2025.
The participation link for the online job session will be sent to those who complete the survey form.
[Common Eligibility Criteria]
Foreign nationals without any issues regarding visa acquisition or employment in Korea.
Must hold a TOPIK (Test of Proficiency in Korean) level 3 or above.
※ Test scores from March 9, 2023, to March 9, 2025, will be accepted.
However, applicants without language proficiency certification can submit it by August 2025.
[Preferred Qualifications]
At least 2 years of relevant experience after obtaining a bachelor's degree.
※ Master's/Doctoral degree holders (or those expected to obtain such degrees) can count their study period as work experience.
[Open Positions]
10 positions in research and development, including formulation process development (please refer to the job posting for more details).
We look forward to your interest, and the application deadline is 5:00 PM on Sunday, March 9, 2025.